Pertussis Market Size in 7MM is expected to witness a major change in the Study Period 2019-2032 | Companies- Mitsubishi Tanabe Pharma, Sanofi, ILiAD Biotechnologies, Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin

"The Pertussis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Pertussis pipeline products will significantly revolutionize the Pertussis market dynamics"

The Pertussis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Pertussis market size from 2019 to 2032. The report also covers current Pertussis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Key Takeaways from the Pertussis Market Report
• The increased number of pertussis from past few decades, along with the emerging prophylactic treatment, is likely to contribute directly to the Pertussis market growth during the forecast period.
• As per the study by Robert Koch Institute (2020), the use of the pertussis vaccination, on the other hand, has increased in recent years. While 32.7% of adults nationwide had received a pertussis vaccination within the last 10years by 2016, the vaccination rate in 2019 was already 41.9%.
• The leading Pertussis Companies are working in the market include Mitsubishi Tanabe Pharma, Sanofi, ILiAD Biotechnologies, Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet, and others
• Promising Pertussis Pipeline Therapies in the various stages of development include DTwP-HepB-IPV-Hib, BPZE 1, and others
• In January 2022, LiAD Biotechnologies announced that the USFDA has granted Fast Track designation to BPZE1 for active booster immunization against pertussis. BPZE1: ILiAD Biotechnologies is a technologically advanced live attenuated pertussis vaccine that contains genetic modifications to eliminate, attenuate or inactivate three different B. pertussis toxins that are inactivated pertussis toxin, deleted dermonecrotic toxin, and marked reduction in Tracheal toxin to protect against Bordetella pertussis nasal infection (colonization) and active disease through the induction of broad and sustained mucosal and systemic immunity. Based on the positive topline results from ILiADBiotechnologies on the Phase IIb trial of lead pertussis vaccine candidate BPZE1 at the virtual World Vaccine Congress, it met both primary endpoints of overall safety and induction of mucosal immunity

Discover more about therapies set to grab major Pertussis Market Share @ Pertussis Market Size- https://www.delveinsight.com/report-store/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pertussis Overview
Pertussis, literally meaning "a violent cough," and also known as whooping cough, or "the cough of 100 days," was first described in the Paris epidemic of 1578. Bordetella pertussis, the causative organism, was discovered in 1906, and a vaccine was developed in the 1940s. Before the pertussis vaccine was developed, pertussis was a major cause of infant morbidity and mortality.

Pertussis Epidemiology Segmentation in the 7MM
• Age-Specific Vaccination Coverage

Download the report to understand which factors are driving Pertussis Epidemiology Trends @ Pertussis Epidemiological Insights- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pertussis Emerging Drugs

• DTwP-HepB-IPV-Hib: Serum Institute of India
A hexavalent conjugate vaccine (DTwP-HepB-IPV-Hib) is being developed by Serum Institute of India, for the prevention of diphtheria, tetanus, whole-cell pertussis (DTaP), poliomyelitis and Haemophilus influenzae type B (Hib) in infants.

• BPZE 1: ILiAD Biotechnologies
BPZE1 is an investigational live-attenuated intranasal vaccine designed to induce comprehensive and durable protection against Bordetella pertussis (B. pertussis) infection and disease. By blocking B. pertussis colonization in nasal passages, the vaccine may also prevent transmission, thereby reducing the incidence of pertussis disease. The designation is supported by data from 4 clinical trials evaluating BPZE1 in healthy adults.

Pertussis Treatment Market
The prevention of pertussis centers on community vaccination. Recent immunization efforts have focused on adults because they are the primary transmitters of the disease to infants and are at risk of infection themselves. The whole-cell pertussis vaccine in combination with diphtheria and tetanus toxoids was introduced in 1948. Acellular pertussis vaccines were developed after studies raised concerns about a temporal relation between pertussis-containing vaccines and neurologic illnesses, including encephalopathy, infantile spasms, and sudden infant death syndrome. They include representative antigens of pathologic toxins seen in B. pertussis strains.

To know more about Pertussis Treatment options, visit @ Pertussis Drugs- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pertussis Market Dynamics
The Pertussis Market Dynamics is anticipated to change in the coming years owing to the improvement in the Increase in the recommendation of vaccination programs in pregnant women, raising awareness of the diseases, incremental healthcare spending across the world. The vaccine are develope by key players, such as, ILiAD Biotechnologies (BPZE1), Serum Institute of India, Bilthoven Biologicals and Vakzine Projekt Management GmbH (SIIPL Tdap), Mitsubishi Tanabe Pharma Corporation (BK1310/MT2355), that are under late - and mid-phase of clinical development have the potential to create a significant positive shift in Pertussis market size. The launch of emerging therapies is expected during the forecast period of 2023-2032.

Pertussis Market Drivers
• Increase in the recommendation of vaccination programs in pregnant women
• Increasing Awareness Programs
• Increasing population of pertussis

Pertussis Market Barriers
• Acellular vaccines less effective in the current market
• Lack of patient awareness
• Barriers to developing a new whole-cell version of pertussis vaccine
• Different vaccination policies amongst various countries

Learn more about the Pertussis Pipeline Therapies in clinical trials @ Pertussis Market Landscape- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pertussis Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Pertussis Companies- Mitsubishi Tanabe Pharma, Sanofi (NYSE: SAN), ILiAD Biotechnologies, Serum Institute of India, LG Chem, Dynavax Technologies (NYSE: DVAX), Tianjin CanSino Biotechnology, Faron Pharmaceuticals (NYSE: FARON.HE), Kymab, BioNet and others
• Pertussis Pipeline Therapies- DTwP-HepB-IPV-Hib, BPZE 1, and others.
• Pertussis Market Dynamics: Pertussis Market Drivers and Barriers
• Pertussis Market Access and Reimbursement, Unmet Needs, and Future Perspectives

Discover more about Pertussis Drugs in development @ Pertussis Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Pertussis Executive Summary
3. Pertussis Competitive Intelligence Analysis
4. Pertussis: Market Overview at a Glance
5. Pertussis: Disease Background and Overview
6. Patient Journey
7. Pertussis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Pertussis Unmet Needs
10. Key Endpoints of Pertussis Treatment
11. Pertussis Marketed Products
12. Pertussis Emerging Therapies
13. Pertussis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Pertussis Market Outlook
16. Pertussis Market Access and Reimbursement Overview
17. KOL Views
18. Pertussis Market Drivers
19. Pertussis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get in touch with our Business executive @ Pertussis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/pertussis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Published Important Links-

https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.hackster.io/dennydones9
https://letterboxd.com/dennydones9/
https://ko-fi.com/dennydones9
https://wakelet.com/@DennyDones813
https://onedio.com/profil/dennydones9
https://www.lyrics.com/user/349564/dennydones9#google_vignette
https://hypothes.is/users/dennydones9
https://shivambhu-hut.mn.co/posts/exploring-the-axillary-hyperhidrosis-market-innovations-treatments-and-future-prospects
https://zumvu.com/dennydones9/
https://imarticus.org/skillenza/user/dennydones9
https://oppathingzz.mn.co/members/20019648
https://findaspring.org/members/dennydones9/
https://www.poeticous.com/yashveer-bhardwaj
https://git.disroot.org/dennydones9
https://kuula.co/profile/havensmith
https://artmight.com/user/profile/3082810
https://www.credly.com/users/denny-dones/badges
https://quantum-buoyancy.mn.co/posts/axillary-hyperhidrosis-market-size-and-outlook-delveinsight
https://freeline.mn.co/posts/45202136
https://participer.valdemarne.fr/profiles/denny_dones/activity
https://elderassociation.mn.co/posts/45117025
https://www.domestika.org/en/dennydones99
https://nxgen.mn.co/members/19995548
https://www.laclt.com/profile/ybhardwaj/profile
https://stemfemmes.mn.co/posts/emerging-trends-in-managing-hot-flashes-in-the-prostate-cancer-market
https://network-91053.mn.co/posts/45119865
https://autism-support.mn.co/posts/understanding-hot-flashes-in-prostate-cancer-market-size-and-outlook-2032
https://jasa-seo.mn.co/posts/45120226
https://lapp.unl.edu.ec/profiles/dennydones99/activity?locale=en
https://www.storeboard.com/JohnSmith-5965202
https://doodleordie.com/profile/dennydones99
https://macro.market/company/delveinsight-business-research
https://pantip.com/profile/7306022#topics
https://allmylinks.com/dennydonesusa
https://uconnect.ae/read-blog/4382
https://blacksnetwork.net/post/102497_herpetic-keratitis-is-a-condition-that-affects-the-eye-and-is-caused-by-the-herp.html
https://ekonty.com/-dennydones99
https://app.wedonthavetime.org/posts/03e285b9-e449-4c96-b257-8cb7a2b74243
https://www.weddingbee.com/members/dennydones99/
https://community.storytellingwithdata.com/members/me/gallery

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.